Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma

Kouhpayeh, Shirin; Andalib, Alireza; Gharagozloo, Marjan; Sanei, Mohammad Hossein; Esmaeil, Nafiseh; Maracy, Mohammad Reza

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma

Document Type : Original Article

Authors

¹ Department of Immunology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Pathology, Isfahan Medical School, Isfahan University of Medical Sciences, Isfahan, Iran

³ Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The objective of this study is to indicate the role of urokinase plasminogen activator receptor (uPAR), soluble uPAR (suPAR), and β1 integrin in tumor growth and invasion of lymph nodes from Hodgkin's lymphoma (HL) patients. Materials and Methods: In this study, 25 lymph nodes from HL patients were analyzed for the expression of β1 integrin and uPAR on mononuclear cells using two-color flow cytometry and immunohistochemical analysis. Moreover, the levels of suPAR in the serum samples of HL patients were measured and compared with 32 healthy controls. Results: Flowcytometry and immunohistochemical results indicated no significant association of uPAR expression with tumor size, different stages, or different histological subtypes of HL; however, an increased expression of β1 integrin was detected in the advanced stages of HL. Higher expression of β1 integrin was detected in nodular sclerosis compared to lymphocyte predominant. No significant difference was observed between the serum levels of suPAR in patients with different stages of HL and healthy controls. Moreover, the levels of suPAR were significantly higher in nodular sclerosis in comparison with other subtypes. Conclusions: This study showed that the levels of suPAR and β1 integrin varied between different histological subtypes of HL. Although uPAR may play only a minor role in the growth and metastasis of lymphoma, β1 integrin may be important in predicting prognosis and metastasis in HL.

Keywords

References

1.	Deryugina EI, Quigley JP. Cell surface remodeling by plasmin: A new function for an old enzyme. J Biomed Biotechnol 2012;14:1-21.
2.	Béné MC, Castoldi G, Knapp W, Rigolin GM, Escribano L, Lemez P, et al. CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: A review. Leukemia 2004;18:394-400.
3.	Saito K, Takeha S, Shiba K, Matsuno S, Sorsa T, Nagura H, et al. Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: Functional multiplicity of matrix degradation on hematogenous metastasis. Int J Cancer 2000;86:24-9.
4.	Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, et al. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol 2004;172:540-9.
5.	Dear AE, Medcalf RL. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. Eur J Biochem 1998;252:185-93.
6.	Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002;3:932-43.
7.	Tarui T, Andronicos N, Czekay RP, Mazar AP, Bdeir K, Parry GC, et al. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem 2003;278:29863-72.
8.	Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43.
9.	Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008;34:122-36.
10.	Baker EA, Bergin FG, Leaper DJ. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 2000;53:307-12.
11.	Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000;126:641-6.
12.	Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, et al. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. Cancer Epidemiol Biomarkers Prev 2011;20:609-18.
13.	de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004;24:13-39.
14.	Cogliatti SB, Schmid U. Who is WHO and what was REAL? Swiss Med Wkly 2002;132:607-17.
15.	Chiu A, Xu W, He B, Dillon SR, Gross JA, Sievers E, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007;109:729-39.
16.	Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, et al. Hodgkin's lymphoma: The pathologist's viewpoint. J Clin Pathol 2002;55:162-76.
17.	Atfy M, Eissa M, Salah HE, El Shabrawy DA. Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia. Med Oncol 2012;29:2063-9.
18.	Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23-36.
19.	Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003;63:196-206.
20.	Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010;20:161-8.
21.	Das DK. Cytopathology: LC06-1 Hodgkin lymphoma: Diagnostic criteria AND pitfalls. Pathology 2014;46 Suppl 2:S9.
22.	Vinuesa CG, Linterman MA, Goodnow CC, Randall KL. T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 2010;237:72-89.
23.	Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008;205:2251-68.
24.	de la Cruz-Merino L, Lejeune M, Nogales Fernández E, Henao Carrasco F, Grueso López A, Illescas Vacas A, et al. Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: A whole new world with therapeutic implications. Clin Dev Immunol 2012;2012:756353.
25.	Divatia M, Kim SA, Ro JY. IgG4-related sclerosing disease, an emerging entity: A review of a multi-system disease. Yonsei Med J 2012;53:15-34.
26.	Eddy AA. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost 2009;101:656-64.
27.	Molin D, Edström A, Glimelius I, Glimelius B, Nilsson G, Sundström C, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002;119:122-4.
28.	Berger P, Girodet PO, Begueret H, Ousova O, Perng DW, Marthan R, et al. Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis. FASEB J 2003;17:2139-41.

Advanced Biomedical Research